PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32399300-3 2020 Set apart from conventional anthracycline regimens such as epirubicin, pegylated liposomal doxorubicin (Lipo-Dox , PLD) was introduced for providing a justifiable treatment effect, while offering a favorable toxicity profile for breast cancer patients in a metastatic setting. Doxorubicin 91-102 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 115-118 33500617-6 2021 The mechanism was probably attributed to the accumulation of PLD in the skin tissues during the long-term circulation and further the induction of ROS to cause the oxidative damage of keratinocytes owing to the sustained release of doxorubicin from PLD. Doxorubicin 232-243 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 249-252 33500617-6 2021 The mechanism was probably attributed to the accumulation of PLD in the skin tissues during the long-term circulation and further the induction of ROS to cause the oxidative damage of keratinocytes owing to the sustained release of doxorubicin from PLD. Doxorubicin 232-243 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 61-64 33422061-4 2021 This combination achieves the therapeutic function and simultaneously "grabs" Lipo-Dox (PEGylated liposomal doxorubicin, PLD) to enhance the cellular internalization and anticancer activity of PLD. Doxorubicin 109-120 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 194-197 31008727-4 2019 The aim was to determine the impact, in clinical practice, of trabectedin with pegylated liposomal doxorubicin (trabectedin/PLD) on the subsequent platinum-based therapy in these patients, and to explore the prognosis for breast cancer gene status and the expression of diverse genes. Doxorubicin 99-110 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 124-127 28365224-5 2017 The pharmacokinetics and biodistribution investigations indicated DOX could be selectively released from PX in cancer cells triggered by the local overexpressed PLD, and PX could significantly prolong the half-life of DOX in the tumors and decrease the distribution in heart and kidney. Doxorubicin 66-69 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 161-164 28700899-3 2017 In this study our aim was to evaluate the susceptibility of the pegylated liposomal formulation of doxorubicin (PLD/Doxil /Caelyx ) to MDR. Doxorubicin 99-110 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 112-115 28700899-4 2017 We show that cells selected to be resistant to DOX are cross-resistant to PLD and PLD is also ineffective in an allograft model of doxorubicin-resistant mouse B-cell leukemia. Doxorubicin 47-50 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 82-85 28700899-7 2017 Consistent with the higher Pgp levels needed to confer resistance, PLD administration was able to overcome doxorubicin insensitivity of the mouse mammary tumors. Doxorubicin 107-118 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 67-70 23388584-5 2013 Pegylated liposomal doxorubicin (PLD), is considered one of the most active therapeutic options for recurrent or progressive OC. Doxorubicin 20-31 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 33-36 26089893-8 2015 Inhibition of PLD by a general antagonist (1-butanol) or specific inhibitor, halopemide, or N-hexanoylsphingosine, or by cellular ceramides accumulated in doxorubicin-treated hepatocytes decreased insulin-stimulated glucose metabolism. Doxorubicin 155-166 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 14-17 24335366-1 2013 OBJECTIVE: We evaluated the safety and efficacy of pegylated liposomal doxorubicin(PLD)and carboplatin(CBDCA)(CD) for platinum-sensitive recurrent epithelial ovarian cancer. Doxorubicin 71-82 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 83-86 22902994-3 2013 DMsPLN demonstrated enhanced efficacy compared to liposomal Dox (PLD) with up to a 3-fold increase in animal life span, a 10-20% tumor cure rate, undetectable normal tissue toxicity and decreased tumor angiogenesis. Doxorubicin 60-63 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 65-68 26093057-4 2015 Mice deficient in CCL2 or CCL5 demonstrated altered clearance and tissue distribution of polyethylene glycol tagged liposomal doxorubicin (PLD) compared to control mice. Doxorubicin 126-137 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 139-142 26093057-6 2015 Plasma exposure of encapsulated liposomal doxorubicin positively correlated with the total exposure of plasma CCL2 and CCL5 in patients with recurrent epithelial ovarian cancer treated with PLD. Doxorubicin 42-53 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 190-193 23419527-1 2013 The present study aims to evaluate the efficacy of octa-arginine (R8)-modified pegylated liposomal doxorubicin (R8-PLD) for the treatment of non-small cell lung cancer, for which the primary treatment modality currently consists of surgery and radiotherapy. Doxorubicin 99-110 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 115-118 23419527-3 2013 In vitro analysis with the non-small cell lung cancer cell line, A549 confirmed the efficient cellular accumulation of Dox, delivered by R8-PLD compared to PLD. Doxorubicin 119-122 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 140-143 23419527-9 2013 This suggested system improved the delivery efficiency of Dox in selected model of cancer which supports the potential usefulness of R8-PLD in cancer treatment, lung cancer in particular. Doxorubicin 58-61 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 136-139 23863745-0 2013 [A case of recurrent endometrial carcinoma with pleural effusion maintained long SD by pegylated liposomal doxorubicin(PLD)chemotherapy]. Doxorubicin 107-118 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 119-122 23863745-1 2013 We experienced a case of long SD through the use of pegylated liposomal doxorubicin(PLD)chemotherapy for recurrent endometrial carcinoma with pleural effusion. Doxorubicin 72-83 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 84-87 20352294-1 2011 PURPOSE: Pemetrexed and pegylated liposomal doxorubicin (PLD) are clinically active as single agents and preclinically synergistic. Doxorubicin 44-55 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 57-60 17251657-6 2006 Liposomal doxorubicin (PLD) has been shown to be useful in the treatment of soft tissue sarcomas, and our case supports its use in cardiac angiosarcoma. Doxorubicin 10-21 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 23-26 20945566-4 2004 As a consequence, a pegylated liposomal NP preparation of DOX (PLD) was developed and shown to have a long blood circulation half-life (2-3 days versus 5 min for free DOX) and had a very high accumulation in tumors compared to the normal surrounding tissue. Doxorubicin 58-61 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 63-66 20945566-4 2004 As a consequence, a pegylated liposomal NP preparation of DOX (PLD) was developed and shown to have a long blood circulation half-life (2-3 days versus 5 min for free DOX) and had a very high accumulation in tumors compared to the normal surrounding tissue. Doxorubicin 167-170 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 63-66 20945566-5 2004 In addition, PLD alone had a superior treatment outcome (in comparison to DOX used at the same concentration in combination with two other chemotherapeutic agents) and showed lower toxicity (5). Doxorubicin 74-77 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 13-16 18701868-1 2008 Pegylated liposomal doxorubicin (Doxil: PLD) is a liposome-encapsulated form of doxorubicin modified with polyethylene glycol that has been approved for the treatment of AIDS-related Kaposi"s sarcoma. Doxorubicin 20-31 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 40-43 18701868-1 2008 Pegylated liposomal doxorubicin (Doxil: PLD) is a liposome-encapsulated form of doxorubicin modified with polyethylene glycol that has been approved for the treatment of AIDS-related Kaposi"s sarcoma. Doxorubicin 80-91 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 40-43 18701868-2 2008 The characteristics of PLD are reduction of the severe side effects of cardiac toxicity and myelosuppression seen with doxorubicin, and a higher anti-tumor effect from the selective high maintenance of the drug concentration in the tumor tissue. Doxorubicin 119-130 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 23-26 15717735-7 2004 In pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), this delivery system encapsulates doxorubicin within polyethylene glycol-coated liposomes, leading to promising new applications for a well-established drug. Doxorubicin 23-34 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 50-53 15717739-3 2004 Pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), is the only liposomal anthracycline indicated for second-line treatment of platinum- and paclitaxel-refractory ovarian cancer. Doxorubicin 20-31 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 47-50 15717735-7 2004 In pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), this delivery system encapsulates doxorubicin within polyethylene glycol-coated liposomes, leading to promising new applications for a well-established drug. Doxorubicin 91-102 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 50-53 15717740-12 2004 The optimal dose of PLD is lower than that of conventional doxorubicin or NPLD. Doxorubicin 59-70 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 20-23 15717735-8 2004 Liposome-encapsulated doxorubicin citrate complex (Myocet [NPLD]), another liposomal delivery system for doxorubicin, lacks the polyethylene glycol coating, resulting in much shorter circulation times than those of PLD. Doxorubicin 22-33 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 60-63 15717742-4 2004 Direct comparisons to conventional doxorubicin therapy showed comparable efficacy but significantly lower risk of cardiotoxicity with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) therapy. Doxorubicin 154-165 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 181-184 15717736-1 2004 Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (Doxil/Caelyx [PLD]), was developed to enhance the safety and efficacy of conventional doxorubicin. Doxorubicin 17-28 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 84-87 15717736-1 2004 Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (Doxil/Caelyx [PLD]), was developed to enhance the safety and efficacy of conventional doxorubicin. Doxorubicin 156-167 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 84-87 15717744-4 2004 Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi"s sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]). Doxorubicin 201-212 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 228-231 12736762-2 2003 Long-circulating polyethylene glycol-coated (PEGylated) liposomal doxorubicin (PLD) has low systemic toxicity. Doxorubicin 66-77 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 79-82 15289836-4 2004 Nonetheless, the challenge to increase the tumor response to chemotherapy while keeping low the cardiac risk may be now met by the use of a recently introduced polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD). Doxorubicin 209-220 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 222-225 34841717-2 2022 Preclinical data demonstrated that depletion of arginine by PEGylated arginine deiminase (ADI-PEG 20) enhanced liposomal doxorubicin (PLD) cytotoxicity in cancer cells with argininosuccinate synthase 1 (ASS1) deficiency. Doxorubicin 121-132 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 134-137 11750714-1 2002 Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) is a new formulation of doxorubicin with peculiar pharmacokinetic and pharmacodinamic properties, a favorable toxic profile and a demonstrated activity in solid tumors. Doxorubicin 49-60 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 62-65 11750714-1 2002 Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) is a new formulation of doxorubicin with peculiar pharmacokinetic and pharmacodinamic properties, a favorable toxic profile and a demonstrated activity in solid tumors. Doxorubicin 91-102 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 62-65 10811504-2 2000 Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) has long circulation time and enhanced drug accumulation in the tumor tissues. Doxorubicin 49-60 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 62-65 34128757-1 2021 INTRODUCTION: : The efficacy and safety of trabectedin/pegylated liposomal doxorubicin (trabectedin/PLD) in patients with recurrent ovarian cancer have been demonstrated in randomized clinical studies. Doxorubicin 75-86 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 100-103